Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Chemotherapy in Esophageal Squamous Cell Carcinoma
NCT06304974Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Biokin Pharmaceutical. Started Mar 2024; status: active, not recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06304974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304974.